公开(公告)号：US20230099258A1

公开(公告)日：2023-03-30

申请号：US17711205

申请日：2022-04-01

Applicant: Novartis AG

Inventor： Gary GLICK ,  Shomir GHOSH ,  William R. ROUSH

IPC: C07D263/46 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07D295/096 ,  C07D213/34 ,  C07D307/64 ,  C07D311/54 ,  C07D213/71 ,  C07D277/36 ,  C07C317/22

Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

公开(公告)号：US11597706B2

公开(公告)日：2023-03-07

申请号：US16094491

申请日：2017-04-18

Applicant: Novartis AG

Inventor： Gary Glick ,  Shomir Ghosh ,  William R. Roush

IPC: C07C317/22 ,  C07D295/096 ,  C07D213/34 ,  C07D263/46 ,  C07D333/34 ,  C07D405/12 ,  C07D417/12 ,  C07D307/64 ,  C07D311/54 ,  C07D213/71 ,  C07D277/36

Abstract: In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

公开(公告)号：US20180370911A1

公开(公告)日：2018-12-27

申请号：US16019914

申请日：2018-06-27

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： GARRET MIYAKE ,  BIN LIU ,  CHERN-HOOI LIM

IPC: C07C319/14 ,  C07D213/70 ,  C07D239/38 ,  C07D277/74 ,  C07D235/28 ,  C07D311/54 ,  C07D215/36 ,  C07D285/16

Abstract: In one aspect, the invention provides a method of promoting a carbon-sulfur bond forming reaction. In certain embodiments, the reaction comprises cross-coupling of a(n) (hetero)aryl halide with a thiol to form the carbon-sulfur bond, wherein the method is promoted by light irradiation in the absence of a photocatalyst. In other embodiments, the cross-coupling reaction can be promoted through visible light irradiation, including sunlight.

公开(公告)号：US09975869B2

公开(公告)日：2018-05-22

申请号：US14780214

申请日：2014-04-04

Applicant: Sphaera Pharma Pvt. Ltd.

Inventor： Sundeep Dugar ,  Dinesh Mahajan ,  Kumar Santosh Rai ,  Sarbjit Singh ,  Ishwar Rakesh Patil

IPC: C07D311/62 ,  C07D311/60 ,  C07C45/71 ,  C07C45/72 ,  C07D311/54 ,  C07D405/12 ,  A23L33/10

CPC classification number: C07D311/62 ,  A23L33/10 ,  C07C45/71 ,  C07C45/72 ,  C07D311/54 ,  C07D311/60 ,  C07D405/12

Abstract: The present invention provides novel analogs of epicatechin and related polyphenols, their variously functionalized derivatives, process for preparation of the same, composition comprising these compounds and their method of use.

公开(公告)号：US5672607A

公开(公告)日：1997-09-30

申请号：US011183

申请日：1993-01-29

Applicant: Michael R. Boyd ,  John H. Cardellina, II ,  Kirk R. Gustafson ,  Laurent A. Decosterd ,  Ian Parsons ,  Lewis Pannell ,  James B. McMahon ,  Gordon M. Cragg

Inventor： Michael R. Boyd ,  John H. Cardellina, II ,  Kirk R. Gustafson ,  Laurent A. Decosterd ,  Ian Parsons ,  Lewis Pannell ,  James B. McMahon ,  Gordon M. Cragg

IPC: C07D211/46 ,  A61K31/00 ,  A61K31/12 ,  A61K31/35 ,  A61K31/352 ,  A61K31/37 ,  A61K31/505 ,  A61K31/52 ,  A61K31/70 ,  A61K38/00 ,  A61K38/17 ,  A61K38/21 ,  A61K45/06 ,  A61P31/00 ,  A61P31/12 ,  A61P31/18 ,  C07C46/00 ,  C07C46/10 ,  C07C50/32 ,  C07D311/46 ,  C07D311/54 ,  C07D311/56 ,  C07D311/92 ,  A61K31/44

CPC classification number: C07D311/92 ,  A61K31/12 ,  A61K31/35 ,  A61K31/352 ,  A61K31/37 ,  A61K31/70 ,  A61K38/1774 ,  A61K38/212 ,  A61K45/06 ,  C07C46/00 ,  C07C46/10 ,  C07C50/32 ,  C07D311/56

Abstract: The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.

Abstract translation: 本发明提供了新的抗病毒萘醌化合物，其可以根据本发明的方法从科氏菌属植物中分离或者化学合成。 抗病毒萘醌酮化合物，其衍生物及其前药可以单独使用或与组合物如药物组合物中的其它抗病毒剂组合使用，以抑制病毒如逆转录病毒，特别是人的生长或复制 免疫缺陷病毒，特别是HIV-1或HIV-2，用于治疗或预防病毒感染。

公开(公告)号：US5521216A

公开(公告)日：1996-05-28

申请号：US182028

申请日：1994-05-12

Applicant: Yasushi Igarashi ,  Takuji Yamaguchi ,  Kunio Hosaka

Inventor： Yasushi Igarashi ,  Takuji Yamaguchi ,  Kunio Hosaka

IPC: A61K31/35 ,  A61K31/352 ,  A61P3/08 ,  A61P3/10 ,  A61P13/02 ,  A61P15/00 ,  A61P27/02 ,  A61P27/12 ,  C07D311/54 ,  C07D311/16

CPC classification number: C07D311/54

Abstract: The present invention relates to a chromone derivative of formula (1): ##STR1## (wherein R.sub.1 and R.sub.2 are the same or different and independently represent a hydrogen atom or a lower alkyl group) as well as a synthetic intermediate thereof and an aldose reductase inhibitor comprising said derivative as an active ingredient. The chromone derivatives of the present invention can be easily synthesized, and are useful as aldose reductase inhibitor with an excellent inhibitory action on aldose reductase.

Abstract translation: PCT No.PCT / JP93 / 00699 Sec。 371日期：1994年5月12日 102（e）日期1994年5月12日PCT提交1993年5月26日PCT公布。 第WO93 / 24477号PCT公告 本发明涉及式（1）的色酮衍生物：其中R1和R2相同或不同并且独立地表示氢原子或低级烷基）作为 以及其合成中间体和包含所述衍生物作为活性成分的醛糖还原酶抑制剂。 本发明的色酮衍生物可以容易地合成，可用作对醛糖还原酶具有优异抑制作用的醛糖还原酶抑制剂。

公开(公告)号：US5176737A

公开(公告)日：1993-01-05

申请号：US652705

申请日：1991-02-07

Applicant: Ewan J. T. Chrystal ,  John E. D. Barton ,  David Cartwright ,  Christopher J. Mathews

Inventor： Ewan J. T. Chrystal ,  John E. D. Barton ,  David Cartwright ,  Christopher J. Mathews

IPC: A01N43/80 ,  C07D261/20 ,  C07D311/54 ,  C07D413/12

CPC classification number: C07D413/10 ,  A01N43/80 ,  C07D261/20

Abstract: A herbicidal compound of formula (I): ##STR1## in which Ar is an optionally substituted aryl or heterocyclic ring system:R.sup.1 and R.sup.2 are independently selected from H, optionally substituted alkyl, alkenyl or akynyl, halogen, NR.sup.a R.sup.b, or R.sup.1 and R.sup.2 together with the carbon to which they are attached form an optionally substituted alkenyl or cycloalkyl group;R.sup.3 is CO.sub.2 R.sup.4, CN, COR.sup.4, CH.sub.2 OR.sup.4, CH.sub.4 (OH)R.sup.4, CH(OR.sup.4)R.sup.5, CH.sub.2 OSO.sub.6 R.sup.4, CH.sub.2 OSO.sub.6 R.sub.4, CH.sub.2 ONR.sup.6 R.sup.7, CSNH.sub.2, COSR.sup.4, SCOR.sup.4, COHNSO.sub.2 R.sup.4, CONR.sup.6 R.sup.7, CONHNR.sup.6 R.sup.7, CONHN.sup.+ R.sup.6 R.sup.7 R.sup.8 Y.sup.-2, CO.sub.2.sup.- M.sup.+ or COON.dbd.CR.sup.6 R.sup.7 ;M.sup.+ is an agriculturally acceptable cation;Y.sup.- is an agriculturally acceptable anion;R.sup.4, and R.sup.5 are independently selected from H or an optionally substituted alkyl, aryl, alkenyl or alkynyl group;R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.a and R.sup.b are independently selected from H or an optionally substituted alkyl alkenyl, aryl or akynyl group or any two of R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.a and R.sup.b together with the atom to which they are attached form a cycloalkyl or heterocyclic ring;R.sup.6 and R.sup.7 may also be a heterocyclic ring;W is O or NR.sup.10 where R.sup.10 is H or lower alkyl;X is (CH.sub.2).sub.n, CH.dbd.CH, CH(OR.sup.c)CH.sub.2, COCH.sub.2 ;where R.sup.c is H or an optionally substituted alkyl, aryl, alkynyl or alkynyl group; andn is O, 1 or 2.

公开(公告)号：US3049550A

公开(公告)日：1962-08-14

申请号：US750460

申请日：1960-01-13

Applicant: MERCK & CO INC

Inventor： CLAUDE SPENCER ,  EDWARD WALTON

IPC: C07C65/03 ,  C07C65/19 ,  C07D311/54 ,  C07H17/075

CPC classification number: C07D311/54 ,  C07C65/03 ,  C07C65/19 ,  C07H17/075 ,  Y10S435/886

公开(公告)号：US11819492B2

公开(公告)日：2023-11-21

申请号：US17547501

申请日：2021-12-10

Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Universite ,  Universite de Poitiers ,  Centre Hospitalier Universitaire de Poitiers

Inventor： Stéphane Bach ,  Marie-Thérèse Dimanche-Boitrel ,  Claire Delehouze ,  Thierry Hauet

IPC: A61K31/352 ,  A61P27/02 ,  A61P25/00 ,  A61K45/06 ,  C07D311/20 ,  C07D311/54

CPC classification number: A61K31/352 ,  A61K45/06 ,  A61P25/00 ,  A61P27/02 ,  C07D311/20 ,  C07D311/54

Abstract: The present invention relates to a compound of the following general formula (I):




or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

公开(公告)号：US10703735B2

公开(公告)日：2020-07-07

申请号：US16519856

申请日：2019-07-23

Applicant: Lead Discovery Center GmbH ,  Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.

Inventor： Raffaella Di Lucrezia ,  Tim Bergbrede ,  Peter Nussbaumer ,  Uwe Koch ,  Bert Klebl ,  Axel Choidas ,  Anke Unger ,  Nils-Göran Larsson ,  Maria Falkenberg-Gustafsson ,  Claes M. Gustafsson

IPC: C07D311/04 ,  C07D311/54 ,  C07D413/12 ,  C07D407/14 ,  C07D407/12

Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.